| Name | Title | Contact Details |
|---|
Xperience Restaurant Group (XRG) is a leading operator of casual and fine dining restaurants specializing in Mexican cuisine. Founded in 1954 with its flagship brand, El Torito, the company has grown to operate approximately 56 to 68 restaurants across the United States, serving over 10 million guests annually and employing a dedicated team of more than 3,400 to 4,300 members. XRGs portfolio features well-known brands such as El Torito, Chevys Fresh Mex, and SOL Mexican Cocina, each offering unique dining experiences that highlight authentic Mexican flavors. The company is recognized for its innovative concepts, including Taco Tuesday and tableside presentations, which have significantly influenced the Mexican dining scene in the U.S. XRG is committed to delivering high-quality cuisine in a welcoming environment, focusing on both traditional flavors and culinary innovation to enhance guest experiences.
Purposeful Design is a Christian ministry that exists to help rebuild lives of individuals who have struggled with addiction, homelessness, incarceration and other obstacles; to equip them with valuable work skills; and to provide the gift of work (Genesis 2:15, Matthew 28:16-20, Ephesians 2:8-10).
The Ken Ganley Automotive Group is the fastest growing dealership group in Northeast Ohio and beyond! We currently rank #1 in Ohio and #14 in the country. Our group is a collection of best-in-class dealerships that offer a wide array of quality new and used car models in convenient locations. At the Ken Ganley Auto Group, we believe that our people are our most important assets, along with our culture of leadership, integrity, customer focus and teamwork. Our people are the foundation of our brand, and our success is dependent on preserving our reputation of respect and quality. We are a company that believes in our core values and upholding them through great people, high standards and best practices. The core values of our organization are what shape every action we take and every decision that is made. We are defined by our integrity. We believe in doing what is right for our fellow team members, our customers and our corporate partners. We are responsive, professional, and handle every experience honestly and with class. Together, we have created an image that has resulted in a positive public perception. The image of a leader. Our customers are our #1 priority. We treat them like family, working hard to exceed their expectations. We are committed to continuing our tradition of success, performance and quality customer service. Our team members are entrusted to make sure each and every customer feels valued and listened to. When a customer enters our dealerships, they know they will have a dependable, quality experience every time. Thanks for visiting our page and well see you soon in the showrooms!
Creative Bus Sales is now Model 1 Commercial Vehicles. Nothing about passion or our leadership has changed, and our brand represents the creativity, expertise, and vision we put to work for customers across the U.S. As the largest bus and commercial transit dealership in the U.S., Model 1 is at the forefront of solving commercial and community transportation issues with visionary thinking – including not just vehicles but also distribution, parts, service, F&I, and more. Strong partnerships with more than 20 top manufacturers, the largest in-stock vehicle inventory in the country, and a nationwide team of experts, means theres no problem too big or too unique to solve together. Model 1 is the blueprint for creative commercial vehicle solutions. See why at model1.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.